Humanigen Inc (fka HGENQ)

[Knuckle Sandwich]

Thanks Jay, that last paragraph is very exciting.

CAR-T cell therapy is currently limited by the risk of life-threatening CRS and
neurologic toxicity. These side effects limit both the number of patients that can be treated
with CAR-T and the dosage that can be safely administered. They also require intensive
hospital monitoring of CAR-T patients during therapy. Lenzilumab could aid in the
expansion of CAR-T by allowing for a higher CAR-T dose, potentially improving efficacy
and reducing patient hospitalization. Hospitals now must ensure that a place in the ICU is
available for each CAR-T patient prior to treatment, limiting the potential for true outpatient
administration and adding significant costs and patient management hurdles to the
therapy. Current treatment for CRS mostly revolves around tocilizumab, an IL-6 receptor
antagonist, which treats some but not all cases of CRS, but is not effective as a
prophylaxis or treatment of neurotoxicity. An anti-GM-CSF approach with lenzilumab
could prevent neurotoxicity and CRS, a potential key differentiator in clinical practice. Lenzilumab
is poised to not only improve the clinical management and patient outcomes of CAR-T cell
therapy, but also significantly reduce hospitalization costs, while enabling the treatment of
more patients.

https://9e234b13-0cc4-4c74-b924-d7874342289e.filesusr.com/ugd/6ca631_da982beaeaea4f19a576cc8f37bf0215.pdf